CNTB
Connect Biopharma Holdings Limited
Biotechnology
Market Cap$130M
5Y Perf.-87.4%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
CNTB vs DBVT vs ABBV vs ALKS
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.-62.5%
ABBV
AbbVie Inc.
Drug Manufacturers - General
Market Cap$358.42B
5Y Perf.+87.2%
ALKS
Alkermes plc
Biotechnology
Market Cap$5.90B
5Y Perf.+89.5%
CNTB vs DBVT vs ABBV vs ALKS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CNTB | DBVT | ABBV | ALKS |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Drug Manufacturers - General | Biotechnology |
| Market Cap | $130M | $1712.35T | $358.42B | $5.90B |
| Revenue (TTM) | $26M | $0.00 | $61.16B | $1.56B |
| Net Income (TTM) | $-57M | $-168M | $4.23B | $153M |
| Gross Margin | 95.6% | — | 70.2% | 65.4% |
| Operating Margin | -223.4% | — | 26.7% | 12.3% |
| Forward P/E | — | — | 14.3x | 24.8x |
| Total Debt | $178K | $22M | $69.07B | $70M |
| Cash & Equiv. | $78M | $194M | $5.23B | $1.12B |
CNTB vs DBVT vs ABBV vs ALKS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CNTB
DBVT
ABBV
ALKS
| Stock | Mar 21 | May 26 | Return |
|---|---|---|---|
| Connect Biopharma H… (CNTB) | 100 | 12.6 | -87.4% |
| DBV Technologies S.… (DBVT) | 100 | 37.5 | -62.5% |
| AbbVie Inc. (ABBV) | 100 | 187.2 | +87.2% |
| Alkermes plc (ALKS) | 100 | 189.5 | +89.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNTB vs DBVT vs ABBV vs ALKS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ABBV leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Connect Biopharma Holdings Limited is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. ALKS also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
CNTB
Connect Biopharma Holdings Limited
The Growth Leader
CNTB is the #2 pick in this set and the best alternative if growth and momentum is your priority.
- 72.2% revenue growth vs DBVT's -100.0%
- +191.3% vs ABBV's +11.3%
Best for: growth and momentum
DBVT
DBV Technologies S.A.
The Secondary Option
DBVT lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
ABBV
AbbVie Inc.
The Income Pick
ABBV carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 13 yrs, beta 0.34, yield 3.2%
- Rev growth 8.6%, EPS growth -0.8%, 3Y rev CAGR 1.8%
- 295.5% 10Y total return vs ALKS's -11.0%
- Beta 0.34, yield 3.2%, current ratio 0.67x
Best for: income & stability and growth exposure
ALKS
Alkermes plc
The Defensive Pick
ALKS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- 9.8% margin vs CNTB's -220.1%
- 5.4% ROA vs DBVT's -89.0%
Best for: sleep-well-at-night
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CNTB | 72.2% revenue growth vs DBVT's -100.0% |
| Value | ABBV | Better valuation composite |
| Quality / Margins | ALKS | 9.8% margin vs CNTB's -220.1% |
| Stability / Safety | ABBV | Beta 0.34 vs DBVT's 1.26 |
| Dividends | ABBV | 3.2% yield; 13-year raise streak; the other 3 pay no meaningful dividend |
| Momentum (1Y) | CNTB | +191.3% vs ABBV's +11.3% |
| Efficiency (ROA) | ALKS | 5.4% ROA vs DBVT's -89.0% |
CNTB vs DBVT vs ABBV vs ALKS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
FY 2025
FY 2025
CNTB vs DBVT vs ABBV vs ALKS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLABBVLAGGINGDBVT
Who Leads Where
ABBV leads in 2 of 6 categories
ALKS leads 2 • CNTB leads 1 • DBVT leads 0 • 1 tied
Explore the data ↓DBVTDBV Technologies S.A.
0leads
CNTBConnect Biopharma Hol…
1leads
ALKSAlkermes plc
2leads
ABBVAbbVie Inc.
2leads
6 Total Categories
CATEGORYLEADERvs ALKSvs CNTBMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ABBV3/6
Valuation MetricsMultiples, price ratios, and targets
ALKS2/5
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ALKS4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CNTB3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
ABBV1/1
Income & Cash Flow (Last 12 Months)
ABBV leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ABBV and DBVT operate at a comparable scale, with $61.2B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to CNTB's -2.2%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … | ABBVAbbVie Inc. | ALKSAlkermes plc |
|---|---|---|---|---|
| RevenueTrailing 12 months | $26M | $0 | $61.2B | $1.6B |
| EBITDAEarnings before interest/tax | -$57M | -$112M | $24.5B | $212M |
| Net IncomeAfter-tax profit | -$57M | -$168M | $4.2B | $153M |
| Free Cash FlowCash after capex | -$54M | -$151M | $18.7B | $392M |
| Gross MarginGross profit ÷ Revenue | +95.6% | — | +70.2% | +65.4% |
| Operating MarginEBIT ÷ Revenue | -2.2% | — | +26.7% | +12.3% |
| Net MarginNet income ÷ Revenue | -2.2% | — | +6.9% | +9.8% |
| FCF MarginFCF ÷ Revenue | -2.1% | — | +30.6% | +25.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -99.8% | — | +10.0% | +28.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.6% | +91.5% | +57.4% | -4.1% |
ABBV leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
ALKS leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
At 24.8x trailing earnings, ALKS trades at a 71% valuation discount to ABBV's 85.5x P/E. On an enterprise value basis, ABBV's 15.0x EV/EBITDA is more attractive than ALKS's 17.3x.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … | ABBVAbbVie Inc. | ALKSAlkermes plc |
|---|---|---|---|---|
| Market CapShares × price | $130M | $1712.35T | $358.4B | $5.9B |
| Enterprise ValueMkt cap + debt − cash | $51M | $1712.35T | $422.3B | $4.9B |
| Trailing P/EPrice ÷ TTM EPS | -8.32x | -0.76x | 85.50x | 24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 14.28x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 14.96x | 17.25x |
| Price / SalesMarket cap ÷ Revenue | 4.97x | — | 5.86x | 4.00x |
| Price / BookPrice ÷ Book value/share | 1.40x | 0.66x | — | 3.28x |
| Price / FCFMarket cap ÷ FCF | — | — | 20.12x | 12.28x |
ALKS leads this category, winning 2 of 5 comparable metrics.
Profitability & Efficiency
ALKS leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
ABBV delivers a 62.1% return on equity — every $100 of shareholder capital generates $62 in annual profit, vs $-130 for DBVT. CNTB carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs DBVT's 4/9, reflecting strong financial health.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … | ABBVAbbVie Inc. | ALKSAlkermes plc |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -80.4% | -130.2% | +62.1% | +8.8% |
| ROA (TTM)Return on assets | -69.4% | -89.0% | +3.1% | +5.4% |
| ROICReturn on invested capital | -3.4% | — | +23.9% | +18.9% |
| ROCEReturn on capital employed | -23.2% | -145.7% | +21.5% | +14.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 6 | 7 |
| Debt / EquityFinancial leverage | 0.00x | 0.13x | — | 0.04x |
| Net DebtTotal debt minus cash | -$78M | -$172M | $63.8B | -$1.0B |
| Cash & Equiv.Liquid assets | $78M | $194M | $5.2B | $1.1B |
| Total DebtShort + long-term debt | $178,000 | $22M | $69.1B | $70M |
| Interest CoverageEBIT ÷ Interest expense | -5993.94x | -189.82x | 3.28x | 32.30x |
ALKS leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CNTB leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ABBV five years ago would be worth $20,131 today (with dividends reinvested), compared to $1,500 for CNTB. Over the past 12 months, CNTB leads with a +191.3% total return vs ABBV's +11.3%. The 3-year compound annual growth rate (CAGR) favors CNTB at 25.5% vs ALKS's 4.6% — a key indicator of consistent wealth creation.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … | ABBVAbbVie Inc. | ALKSAlkermes plc |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.5% | +4.9% | -10.1% | +25.3% |
| 1-Year ReturnPast 12 months | +191.3% | +110.4% | +11.3% | +16.5% |
| 3-Year ReturnCumulative with dividends | +97.5% | +19.7% | +50.4% | +14.5% |
| 5-Year ReturnCumulative with dividends | -85.0% | -69.1% | +101.3% | +60.9% |
| 10-Year ReturnCumulative with dividends | -87.4% | -87.0% | +295.5% | -11.0% |
| CAGR (3Y)Annualised 3-year return | +25.5% | +6.2% | +14.6% | +4.6% |
CNTB leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CNTB and ALKS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CNTB is the less volatile stock with a -0.14 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.7% from its 52-week high vs CNTB's 61.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … | ABBVAbbVie Inc. | ALKSAlkermes plc |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.14x | 1.26x | 0.34x | 1.06x |
| 52-Week HighHighest price in past year | $3.82 | $26.18 | $244.81 | $36.60 |
| 52-Week LowLowest price in past year | $0.70 | $7.53 | $176.57 | $25.17 |
| % of 52W HighCurrent price vs 52-week peak | +61.0% | +76.3% | +82.8% | +96.7% |
| RSI (14)Momentum oscillator 0–100 | 42.8 | 48.1 | 46.8 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 272K | 252K | 5.8M | 2.3M |
Evenly matched — CNTB and ALKS each lead in 1 of 2 comparable metrics.
Analyst Outlook
ABBV leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Analyst consensus: CNTB as "Buy", DBVT as "Buy", ABBV as "Buy", ALKS as "Buy". Consensus price targets imply 286.3% upside for CNTB (target: $9) vs 24.3% for ALKS (target: $44). ABBV is the only dividend payer here at 3.24% yield — a key consideration for income-focused portfolios.
| Metric | CNTBConnect Biopharma… | DBVTDBV Technologies … | ABBVAbbVie Inc. | ALKSAlkermes plc |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $46.33 | $256.64 | $44.00 |
| # AnalystsCovering analysts | 5 | 15 | 41 | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — | +3.2% | — |
| Dividend StreakConsecutive years of raises | — | 0 | 13 | 0 |
| Dividend / ShareAnnual DPS | — | — | $6.57 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.3% | +0.5% |
ABBV leads this category, winning 1 of 1 comparable metric.
Key Takeaway
ABBV leads in 2 of 6 categories (Income & Cash Flow, Analyst Outlook). ALKS leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
Best OverallAbbVie Inc. (ABBV)Leads 2 of 6 categories
Loading custom metrics...
CNTB vs DBVT vs ABBV vs ALKS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CNTB or DBVT or ABBV or ALKS a better buy right now?
For growth investors, AbbVie Inc.
(ABBV) is the stronger pick with 8. 6% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 8x trailing P/E, making it the more compelling value choice. Analysts rate Connect Biopharma Holdings Limited (CNTB) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CNTB or DBVT or ABBV or ALKS?
On trailing P/E, Alkermes plc (ALKS) is the cheapest at 24.
8x versus AbbVie Inc. at 85. 5x.
03Which is the better long-term investment — CNTB or DBVT or ABBV or ALKS?
Over the past 5 years, AbbVie Inc.
(ABBV) delivered a total return of +101. 3%, compared to -85. 0% for Connect Biopharma Holdings Limited (CNTB). Over 10 years, the gap is even starker: ABBV returned +295. 5% versus CNTB's -87. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CNTB or DBVT or ABBV or ALKS?
By beta (market sensitivity over 5 years), Connect Biopharma Holdings Limited (CNTB) is the lower-risk stock at -0.
14β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately -1009% more volatile than CNTB relative to the S&P 500. On balance sheet safety, Connect Biopharma Holdings Limited (CNTB) carries a lower debt/equity ratio of 0% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
05Which is growing faster — CNTB or DBVT or ABBV or ALKS?
By revenue growth (latest reported year), AbbVie Inc.
(ABBV) is pulling ahead at 8. 6% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Connect Biopharma Holdings Limited grew EPS 74. 1% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CNTB or DBVT or ABBV or ALKS?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -60. 0% for Connect Biopharma Holdings Limited — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -86. 2% for CNTB. At the gross margin level — before operating expenses — CNTB leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CNTB or DBVT or ABBV or ALKS more undervalued right now?
Analyst consensus price targets imply the most upside for CNTB: 286.
3% to $9. 00.
08Which pays a better dividend — CNTB or DBVT or ABBV or ALKS?
In this comparison, ABBV (3.
2% yield) pays a dividend. CNTB, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is CNTB or DBVT or ABBV or ALKS better for a retirement portfolio?
For long-horizon retirement investors, AbbVie Inc.
(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 34), 3. 2% yield, +295. 5% 10Y return). Both have compounded well over 10 years (ABBV: +295. 5%, DBVT: -87. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CNTB and DBVT and ABBV and ALKS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CNTB is a small-cap quality compounder stock; DBVT is a mega-cap quality compounder stock; ABBV is a large-cap income-oriented stock; ALKS is a small-cap quality compounder stock. ABBV pays a dividend while CNTB, DBVT, ALKS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.